HDAC1 and hepatocellular carcinoma: However, there remains a lack of standardized detection protocols for HDAC1/2 in clinical settings, and inhibitors targeting them as therapeutic options (such as HDAC inhibitors) are still in the early stages of clinical trials in HCC.